SeekingAlpha · Oct 14, 2026
Longleaf Partners Fund Q3 2026 Portfolio Review
The market is regaining confidence in Avantorâs ability to grow organically and in Emmanuel Lignerâs turnaround plan.
AB
NASDAQ · ABT
Abbott Laboratories
Healthcare · Medical - Devices
$102.61
Up+$0.01 (+0.01%)
Updated Oct 14, 2026, 5:30 PM
SID Score
6.6/10
Composite research score
Smart Money
48/100
Neutral
- Market cap
- 202.45B
- P/E ratio
- 31.15
- Dividend yield
- 2.30%
- 52-week range
- $81.97 – $129.46
- Volume
- 9.86M
- Avg. volume
- 8.88M
Price performance · ABT
ABT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
ABT closed at $102.61 after 21 trading sessions, up 0.57% for the selected period.
- Last close
- $102.61
- Period change
- +0.57%
- Period low
- $96.69
- Period high
- $103.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $102.59 | $103.435 | $100.631 | $102.61 | 9.86M |
| Oct 12, 2026 | $100.00 | $102.06 | $99.78 | $101.82 | 7.15M |
| Oct 9, 2026 | $98.41 | $100.355 | $98.20 | $99.60 | 6.96M |
| Oct 8, 2026 | $98.56 | $99.20 | $97.20 | $98.49 | 13.91M |
| Oct 7, 2026 | $98.89 | $99.3651 | $97.6205 | $98.73 | 9.39M |
| Oct 6, 2026 | $100.56 | $100.95 | $97.94 | $98.16 | 10.58M |
| Oct 5, 2026 | $97.84 | $100.70 | $97.39 | $100.10 | 11.99M |
| Oct 2, 2026 | $97.25 | $97.59 | $95.06 | $97.50 | 8.71M |
| Oct 1, 2026 | $99.10 | $99.445 | $96.54 | $96.69 | 8.86M |
| Sep 30, 2026 | $100.57 | $100.63 | $98.72 | $98.83 | 7.57M |
| Sep 29, 2026 | $100.26 | $101.07 | $99.4805 | $100.95 | 8.05M |
| Sep 28, 2026 | $101.08 | $101.7619 | $100.255 | $100.98 | 6.8M |
| Sep 25, 2026 | $100.81 | $101.82 | $100.09 | $101.29 | 7.78M |
| Sep 24, 2026 | $103.77 | $104.22 | $101.02 | $101.07 | 6.22M |
| Sep 23, 2026 | $104.22 | $104.31 | $102.66 | $103.49 | 12.18M |
| Sep 22, 2026 | $104.01 | $104.54 | $102.895 | $103.69 | 8.38M |
| Sep 21, 2026 | $102.27 | $103.20 | $101.84 | $102.98 | 5.02M |
| Sep 18, 2026 | $101.83 | $103.19 | $101.50 | $102.61 | 27.08M |
| Sep 17, 2026 | $102.15 | $102.995 | $100.33 | $102.23 | 8.43M |
| Sep 16, 2026 | $101.89 | $103.30 | $101.50 | $102.36 | 5.23M |
| Sep 15, 2026 | $102.98 | $103.06 | $101.47 | $102.03 | 7.42M |
Latest ABT news
The latest Smart Investors Daily articles mentioning ABT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ABT research
Overview
Company profile and research snapshot.
Company profile
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $151.40
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Overweight | — |
| Oct 2, 2026 | Rothschild & Co | Buy | — |
| Sep 8, 2026 | TD Cowen | Buy | — |
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
News briefing
Generated Oct 14, 2026, 3:01 PM
Why Is ABT Down Today? Market Pullback Overshadows Strong Strategic Positioning
Abbott Laboratories declined 0.72% today in a modest pullback that appears disconnected from the company's underlying business momentum. Despite the minor loss, recent coverage highlights ABT's commanding position across high-growth healthcare segments, including neurostimulation and digital health solutions.
Bottom line: Abbott's 0.72% decline appears to be a routine market fluctuation rather than a fundamental deterioration, as the company maintains strong positioning in high-growth segments like neurostimulation and digital health. Investors should focus on ABT's durable competitive advantages and exposure to expanding markets rather than daily price swings, while monitoring competitive intensity in core therapeutic areas.
Yahoo · Oct 14, 2026
Abbott Laboratories (ABT) Is A Key Player In Closed Loop Neurostimulation
Abbott Laboratories (NYSE:ABT) has been identified as a leading group advancing closed-loop neurostimulation in bioelectronic medicine devices. The company is highlighted for closed-loop neurostimulation systems that interact with neural signals to modulate treatment in real time. This focus on bioelectronic medicine complements Abbott's existing work in cardiac and diabetes devices targeting chronic and neurological conditions. The recognition of Abbott's closed-loop neurostimulation push...
Yahoo · Oct 13, 2026
mHealth Solutions Market Forecasts Growth from $109.05B (2026) to $275.44B by 2031, Profiling Philips, Medtronic, Abbott, Dexcom, ResMed & 20 Other Key Players
388-Page Report Delivers 2025 Market Share Rankings, Vendor Valuation Metrics and End-User Buying Criteria as Asia Pacific Emerges as the Fastest-Growing RegionDublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "mHealth Solutions Market: Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. Global mHealth Solutions Market to Reach USD 275.44 Billion by 2031 The global mHealth solutions market is projected to grow from USD 109.05 billion in 2026 to USD 275.44 billion by 2031, regis
Yahoo · Oct 13, 2026
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.
AI research layers
Interpretive context generated from the platform’s current data sources.
Abbott Laboratories Stock Performance
Abbott Laboratories shares closed at $102.67, trading marginally above its 200-day moving average of $102.28 but below its 50-day moving average of $106.09, per SID market data. The stock has declined 18.42% over the trailing twelve months, reflecting broader healthcare sector headwinds. Over the past three months, however, ABT has posted a recovery of 14.46%, suggesting a near-term rebound from recent lows. The one-month return stands at a relatively flat negative 0.13%. According to Massive/Polygon data, the 14-day relative strength index registers at 44.5, placing the stock in neutral territory without immediate overbought or oversold signals. Average daily trading volume sits at approximately 8.88 million shares. Abbott's beta of 0.751 indicates lower volatility relative to the broader market, consistent with its defensive healthcare positioning. The company's market capitalization stands at approximately $202.5 billion.
Abbott Laboratories Valuation Analysis
Abbott Laboratories currently trades at a price-to-earnings ratio of 31.15, reflecting a premium valuation relative to broader market averages, per SID market data. The company's price-to-book ratio stands at 3.90, indicating investors are paying nearly four times book value for each share. The negative PEG ratio of -0.58 suggests that consensus growth estimates have turned negative or that the metric is distorted by unusual earnings trajectory factors, warranting caution in growth-adjusted valuation assessments. According to SEC filings, Abbott maintains a dividend yield of 2.06%, providing income-oriented investors with a steady return component. As a healthcare conglomerate spanning diagnostics, medical devices, nutrition, and pharmaceuticals, Abbott's premium multiple reflects the diversified and defensive nature of its revenue streams. The current valuation positions the stock at a level that prices in stable but not aggressive earnings expansion relative to sector peers.
Smart Money Activity for ABT
Abbott Laboratories registers a composite smart money score of 48 out of 100, signaling a neutral institutional positioning, per SID market data. The institutional component scores a perfect 25 out of 25, indicating robust ownership and sustained confidence from large asset managers based on 13F institutional filings. In contrast, the insider trading component scores 9.3 out of 25, reflecting mixed sentiment among company executives. According to SEC Form 4 filings, there have been 17 insider transactions in the last 90 days, comprising 7 purchases and 10 sales. The higher frequency of insider selling relative to buying suggests some degree of profit-taking at current price levels. Dark pool activity scores 8.5 out of 25, indicating below-average off-exchange institutional accumulation. Congressional trading activity scores 5.1 out of 25, showing limited legislative interest in the stock. The divergence between strong institutional ownership and moderate insider selling creates a mixed signal that warrants monitoring for directional shifts.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has delivered consecutive earnings beats in its two most recently reported quarters, according to company earnings reports. In the April 2026 quarter, Abbott posted earnings per share of $1.15 versus an estimate of $1.14, representing a $0.01 positive surprise. The July 2026 quarter showed a slightly wider beat, with actual EPS of $1.31 compared to the $1.28 consensus estimate, a $0.03 upside surprise. Looking ahead, analyst estimates project EPS of $1.42 for both the October 2026 quarters, per consensus data. The sequential step-up from $1.15 to $1.31 and the projected $1.42 reflects an anticipated earnings growth trajectory through the fiscal year. The consistency of modest positive surprises indicates management's pattern of conservative guidance relative to execution. Investors will closely monitor whether Abbott can sustain this beat-and-raise cadence as the company navigates evolving dynamics across its diagnostics and medical device segments.
Wall Street Analyst Ratings for ABT
Wall Street analyst sentiment toward Abbott Laboratories has shifted decisively positive in recent months, per SID consensus data. On October 7, 2026, Barclays initiated coverage with an Overweight rating, adding a new bullish voice to the coverage universe. Rothschild & Co upgraded the stock to Buy from Neutral on October 2, reflecting improved conviction in Abbott's fundamentals. TD Cowen has reiterated its Buy rating twice, on September 8 and August 25, maintaining consistent bullish positioning according to Wall Street analyst reports. Notably, Wolfe Research upgraded ABT to Outperform from Peer Perform on August 13, marking a meaningful shift from a previously neutral stance. Across these five most recent analyst actions, there have been zero downgrades or negative revisions, with two upgrades, two reiterations, and one initiation all carrying positive designations. This unanimously constructive analyst tone suggests broad institutional confidence in Abbott's forward growth and margin profile across its diversified healthcare portfolio.
